DNA Assembly Lead

See more jobs from Flagship Pioneering

almost 3 years old

This job is no longer active

Company Summary:

Tessera Therapeutics is pioneering Gene Writing™— a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Gene Writing holds the potential to become a new category in genetic medicine, building upon recent breakthroughs in gene therapy and gene editing while eliminating important limitations in their reach, utilization, and efficacy. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.

Position Summary:

Tessera Therapeutics is seeking a Leader for High Throughput DNA production as a critical therapeutic reagent to Tessera discovery and development teams. This person will oversee the automaton activities  for therapeutic reagent generation using the latest innovative high throughput platforms.  The platforms will include the rapid synthesis of DNA including large and complex constructs.

Key Responsibilities:

  • Oversee the high throughput automation for the end to end production of DNA for candidate reagent generation
  • Support the build of a team of research associates, scientists and engineers
  • Mentor the team for end to end workflow from construct design through to the purification of DNA for high throughput reagent production
  • Manage a team to drive the automated production for 24/7 automated operations of novel and innovative therapeutics.  This includes the strategy build of complex and large constructs
  • Maintain the quality of the reagent production and continuously look to improve methods and identify new technologies to increase efficiency and throughput.
  • Write protocols and technical reports to support drug product clinical development.

Basic Qualifications:

  • MS with 6 - 12 years or PhD with 4-8 years of relevant industrial experience. Degree emphasis in Biochemistry, Chemical Engineering, Molecular Biology, Bioengineering, Genetics or related field is preferred
  • Technical understanding and experience in maintaining the operation workflows of a biopharmaceutical high throughput automated laboratory for end to end production from construct design to purified DNA.
  • Understanding of high throughput production for workflows including DNA and mRNA,
  • A proven track record of producing reagents in high throughput automated lab workflows within specified timelines.
  • Experience of interaction and collaboration with discovery and process development teams.
  • Understanding of the requirements for maintaining biologics reagent quality including requirements for product comparability.
  • Experience in working with technology providers.
  • Demonstrated understanding of the current therapeutic discovery and development process, especially in gene therapy, gene editing, mRNA, RNAi, or antisense
  • A strong self-starter, independent thinker, with a strong attention to detail
  • Excellent communication and presentation skills, capable of conveying technical information in a clear and thorough manner
  • The ability to effectively influence the work of others
  • Eager to work with highly skilled and dynamic teams in a fast-paced, entrepreneurial and technical setting
  • Experience managing multiple bench researchers

 

More About Flagship Pioneering

Flagship Pioneering conceives, creates, resources, and develops first-in-category life sciences companies to transform human health and sustainability. Since its launch in 2000, the firm has, through its Flagship Labs unit, applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $50B in aggregate value. To date, Flagship has deployed over $2.2B in capital toward the founding and growth of its pioneering companies alongside more than $18B of follow-on investments from other institutions. The current Flagship ecosystem comprises 41 transformative companies, including Axcella Health (NASDAQ: AXLA), Denali Therapeutics (NASDAQ: DNLI), Evelo Biosciences (NASDAQ: EVLO), Foghorn Therapeutics (NASDAQ: FHTX), Indigo Ag, Kaleido Biosciences (NASDAQ: KLDO), Moderna (NASDAQ: MRNA), Rubius Therapeutics (NASDAQ: RUBY), Sana Biotechnology, Seres Therapeutics (NASDAQ: MCRB), and Sigilon Therapeutics (NASDAQ: SGTX).

Flagship Pioneering and our ecosystem companies are committed to equal employment opportunity regardless of race, color, ancestry, religion, sex, national origin, sexual orientation, age, citizenship, marital status, disability, gender identity or Veteran status.

 

Recruitment & Staffing Agencies:  Flagship Pioneering and its affiliated Flagship Lab companies (collectively, “FSP”) do not accept unsolicited resumes from any source other than candidates.  The submission of unsolicited resumes by recruitment or staffing agencies to FSP or its employees is strictly prohibited unless contacted directly by Flagship Pioneering’s internal Talent Acquisition team.   Any resume submitted by an agency in the absence of a signed agreement will automatically become the property of FSP, and FSP will not owe any referral or other fees with respect thereto.